Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib Versus Vinblastine in Pediatric and AYA Patients With Low Grade Glioma
NCT05180825Phase 2Recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- May 2022
- Primary completion
- Nov 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trametinib in glioma, Mixed glioneuronal tumors and pleomorphic xanthoastrocytoma (PXA) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Progression-Free Survival at 3 years. Started May 2022; status: recruiting.
02
Drugs
trametinib
03
Conditions
gliomaMixed glioneuronal tumorspleomorphic xanthoastrocytoma (PXA)
Beyond the preview
Go deeper on NCT05180825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180825.